BofA analyst Michael Ryskin downgraded Icon (ICLR) to Neutral from Buy with a price target of $195, down from $207.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Icon price target raised to $200 from $185 at Barclays
- Jefferies says market thinking ‘backwards’ on FDA one trial proposal
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Icon’s Hold Rating: Navigating Leadership Transition and Customer Challenges Amid Market Recovery